Baloxavir marboxil

Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus[1].

[1]Frederick G Hayden, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923.|[2]Hideyuki Ikematsu, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med. 2020 Jul 23;383(4):309-320.Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20.|Euro Surveill. 2019 Mar;24(12):1900170.|Front Microbiol. 2021 Feb 12;12:611958.|J Virol. 2021 Apr 14;JVI0040821.|Viruses. 2023 Dec 16, 15(12), 2444.|Antimicrob Agents Chemother. 2021 Aug 23;AAC0113721.|Antimicrob Agents Chemother. 2022 Mar 9;e0000922.|Antivir Res. 2020 Jun;178:104786.|Antiviral Res. 2024 Jul 8:105959.|Bioorg Chem. 1 October 2021, 105388.|Emerg Infect Dis. 2019 Nov;25(11):2108-2111. |Front Microbiol. 2018 Dec 6;9:3026.|Front Pharmacol. 2019 Oct 16;10:1203.|J Antimicrob Chemother. 2020 Dec 22;dkaa527.|J Biol Chem. 2021 Feb 26;100486.|J Infect Dis. 2023 Sep 28:jiad418.|J Virol. 2020 Oct 27;94(22):e00319-20.|Microorganisms. 2020, 8(12), 1968.|Mol Pharm. 2022 Oct 21.|Nat Commun. 2020 Jan 9;11(1):164. |Nat Microbiol. 2020 Jan;5(1):27-33.|Pathogens. 2020 Sep 2;9(9):725.|PLoS Pathog. 2022 Jul 13;18(7):e1010698.|Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8593-8601.|SSRN. 2024 Apr 30.|SSRN. 2024 Aug 7.|The Division of Medical Sciences,Harvard University. 2019 Dec.|University of Alberta . Department of Medical Microbiology and Immunology. 2022 Jan.|Virus Res. 345, July 2024, 199371.|Viruses. 2024 Sep 14.